



***Radiation Therapy as an
Effective Tool to fight cancer
in Women: Future Trends***

R. Sankaranarayanan MD

Screening Group
International Agency for Research on Cancer,
World Health Organization
Lyon, France



CANCER TREATMENT IN DEVELOPING COUNTRIES

- ❖ **Vast range in health service infrastructure**
- ❖ **Wide range in health care resources**

Problems in

- ❖ **Availability**
- ❖ **Accessibility**
- ❖ **Affordability**

CANCER IN WOMEN: BASIC TREATMENT MODALITIES

<i>Cancer site</i>	<i>Surgery</i>	<i>Radiotherapy</i>	<i>Chemotherapy</i>
Breast	++++	++	+++
Cervix	++	++++	++
Body uterus	++++	++	
Ovary	++++	+	+++
Vagina	+	++++	
Vulva	+++	+	

WORLD-WIDE BURDEN OF WOMEN CANCER: AROUND 2002 AD

- ❖ 1 849 000 new cases**
- ❖ 809 000 deaths**
- ❖ 6 354 000 prevalent cases**

WORLD-WIDE BURDEN OF WOMEN CANCER: AROUND 2015 and 2030 AD

	<u>2015</u>	<u>2030</u>
Cases	2 446 000	3 169 000
Deaths	1 081 000	1 442 000

WORLD-WIDE BURDEN OF CERVICAL CANCER: AROUND 2002 AD

- ❖ 493,000 new cases annually
- ❖ 274,000 deaths annually
- ❖ 1.4 million prevalent cases
- ❖ More than 80% in developing countries


■ < 9.4 ■ < 16.8 ■ < 25.8 ■ < 33.4 ■ < 87.3

GLOBOCAN 2002, IARC

WORLD-WIDE BURDEN OF CERVICAL CANCER: AROUND 2015 and 2030 AD

	<u>2015</u>	<u>2030</u>
Cases	645 000	810 000
Deaths	365 000	475 500

5-Year Age Standardised Relative Survival (0-74 yrs)



Cervix Cancer (ICD-10:C53)

- Highest in Seoul, South Korea
- Least in Kampala, Uganda

Intra country variation


- Pronounced in China (urban ↑ vs rural ↓) & India
- No difference in South Korea & Thailand

Data from developed countries


- US-SEER: 70%
- Eurocare: 62%

CERVICAL CANCER CONTROL

- ❖ **Prevention – HPV Vaccines**
- ❖ **Early detection by screening**
- ❖ **Clinical early detection**
- ❖ **Treatment**



Data on stage distribution at time of diagnosis at the Radiumhemmet (Heyman, 1937-1952; Heyman, 1953-1955; Kottmeier, 1958-1961; Kottmeier, 1964-1967; Kottmeier, 1973-1976; Kottmeier, 1979-1982; Pettersson, 1988-1991).



Crude stage-specific 5-year survival compiled from the material followed at the Radiumhemmet (Heyman, 1937-1952; Heyman, 1953-1955; Kottmeier, 1958-1961; Kottmeier, 1964-1967; Kottmeier, 1973-1976; Kottmeier, 1979-1982; Pettersson, 1988-1991)

CANCER OF THE UTERINE CERVIX: RADIOTHERAPY

- ❖ **Radical radiotherapy: Delivered with a curative intention; for stages I-III B; selected cases of IVA**
- ❖ **Concurrent Chemoradiotherapy is an option for stage II and III disease**
- ❖ **Dose delivery reference points: Points A & B**
- ❖ **Post OP RT in high risk early stage disease after surgery**
- ❖ **Palliative radiotherapy**

CANCER OF THE UTERINE CERVIX: RADICAL RADIOTHERAPY


- ❖ **A combination of external-beam pelvic irradiation covering the uterus, parametria and the lymphnodes and intracavitary irradiation for the central disease is used**
- ❖ **The aim is to deliver a total dose of around 80 Gy to point A**

CANCER OF THE UTERINE CERVIX: EXTERNAL RADIOTHERAPY

- ❖ **Parallel pair of portals**
- ❖ **Four-field beam arrangement**
- ❖ **Special midline shields (after 20 Gy in stages I & II; after 40 Gy in stage III)**
- ❖ **40-50 Gy in 20-25 F over 4-5 weeks**

CANCER OF THE UTERINE CERVIX: INTRACAVITARY RADIOTHERAPY

- ❖ **LDR: 1 (for stage III) or 2 (for stages I & II if midline shield is used) applications of 30 Gy to point A**
- ❖ **HDR: 5 weekly applications of 7 Gy to point A (for stages I and II if midline shield is used) or 3 applications of 7 Gy to point A (for stage III)**



- 1 – Tandem
- 2 – Rectal marker
- 3 – Marker seeds
- 4 – Flange
- 5 – Right ovoid
- 6 – Urinary catheter balloon



- 1 – Rectal marker
- 2 – Tandem
- 3 – Ovoids

CANCER OF THE UTERINE CERVIX: PALLIATIVE RADIOTHERAPY

- ❖ **In most cases of IVA and IVB**
- ❖ **30 Gy in 10 F over 2 weeks**

BREAST CANCER IN THE WORLD

- ❖ **1.15 million new cases**
- ❖ **Incidence increasing in most countries**
- ❖ **470 000 deaths**
- ❖ **Half of the global burden in low- and medium-resourced countries**


WORLD-WIDE BURDEN OF BREAST CANCER: AROUND 2015 and 2030 AD

	<u>2015</u>	<u>2030</u>
Cases	1 531 000	2 004 000
Deaths	549 000	737 500


ROLE OF RADIO THERAPY IN BREAST CANCER

- ❖ **Breast conservation**
- ❖ **Adjuvant radiotherapy**
- ❖ **Palliative radiotherapy**


Breast cancer incidence rates (age 35-74) in selected developed countries




Breast cancer incidence rates (age 35-74) in selected developing countries




Breast cancer mortality rates (age 35-74) in selected developed countries



Breast cancer mortality rates (age 35-74) in selected Asian countries



BREAST CONSERVING THERAPY (BCT)





MRM Vs BCT

Randomized trials


Meta-analysis




Comparable local control, Overall survival

Better cosmetic outcome

BCT: EFFECT OF RADIOTHERAPY ON LOCAL RECURRENCE




Node Negative Women




Node Positive Women

BCT: BREAST CANCER AND OVERALL MORTALITY



Breast Cancer Mortality




Overall Mortality

ADJUVANT RADIO THERAPY


Indications of Radiation therapy

- ❖ Patients with 4 or more positive lymph nodes**
- ❖ Presence of extracapsular extension, positive or close margins**
- ❖ T3 tumors with positive lymph nodes, medial quadrant tumors**
- ❖ Any T4 tumors and pectoral fascia involvement**

MASTECTOMY: EFFECT OF RADIOTHERAPY ON LOCAL RECURRENCE




Node negative disease
(1428 women)




Node positive disease
(8505 women)

MASTECTOMY: EFFECT OF RADIOTHERAPY ON BREAST CANCER MORTALITY




Node negative disease
(1428 women)




Node positive disease
(8505 women)



MASTECTOMY: BREAST CANCER AND OVERALL MORTALITY NODE POSITIVE WOMEN



Breast Cancer Mortality



Overall Mortality



Dose: 45Gy/25#/5 wks with 6/10MV LA or telecobalt

RECENT ADVANCES IN RADIOTHERAPY

- ❖ **CT simulators and Portal imaging**
- ❖ **3DCRT**
- ❖ **IMRT**
- ❖ **IGRT**
- ❖ **Portable LA for IORT**
- ❖ **Only 20% of population has access to RT in Africa; 40 % in Asia and 50 % in Latin America**

EARLY DETECTION APPROACHES

- ❖ **Screening: mass application of screening test in asymptomatic populations at regular intervals**
- ❖ **Early clinical diagnosis: detection of early clinical stages of disease in symptomatic or high-risk subjects**

HOW TO DEVELOP CANCER TREATMENT SERVICES IN DEVELOPING COUNTRIES

- ❖ **National policy - NCCP**
- ❖ **Resource allocation/ Phased development**
- ❖ **Human resource development**
- ❖ **Investments in diagnosis/ treatment**
- ❖ **Comprehensive basic services**
- ❖ **Team approach**
- ❖ **National guidelines of Rx**